Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia (Auto-LLC 2001)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00931645|
Recruitment Status : Completed
First Posted : July 2, 2009
Last Update Posted : July 2, 2009
Phase III trial evaluating the role of autologous stem cell transplantation in previously untreated patients under 65 years with stage B and C B-cell chronic lymphocytic leukemia.
Endpoints of the trial :
- major : progression free survival at 3 years
- secondary : overall survival, tolerance, prognostic factors according to baseline clinical stage and biological characteristics (IgHv mutational status, expression of ZAP70 and CD38, cytogenetics).
|Condition or disease||Intervention/treatment||Phase|
|Chronic Lymphocytic Leukemia||Procedure: Autologous stem cell transplantation Procedure: DHAP rescue and Autologous stem cell transplantation Procedure: DHAP rescue and F+C||Phase 3|
All registered patients will be treated with 6 monthly courses of chemotherapy. First three ones will be a CHOP regimen with half dosage of adriamycin, as previously published (Effectiveness of "CHOP" regimen in advanced untreated chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. Lancet ; 1986, i : 1346-1349), followed by three subsequent courses with IV fludarabine (25 mg/sqm d1-5). Patients in CR (NCI, 1996, including CAT scan evaluation) will be then randomized to surveillance without additional treatment or autologous stem cell transplantation using peripheral stem cells collected after the three first courses of chemotherapy, and/or after the completion of the six courses when necessary. For patients not in CR after the six courses, a rescue regimen with the DHAP association ( cisplatin, 100 mg/sqm d1, cytarabine 2 g/sqm d2, dexamethasone 40 mg/sqm d1-4) will precede an additional stem cell collection if necessary, and patient will be randomized between autologous stem cell transplantation and three additional courses of an association of fludarabine (25 mg/sqm d1-3) and cyclophosphamide (300 mg/sqm d1-3). Conditioning regimen will associate TBI (10 grays, d -3-1) and cyclophosphamide (60 mg/sqm d-5-4).
Evaluation for response wil be performed before randomisation and two months after completion of therapy in each arm.
Follow-up data will be registered and monitored every three month during the first year, and then every six month. Criteria for evaluation of response will use the NCI system (1996).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||241 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia|
|Study Start Date :||April 2001|
|Actual Primary Completion Date :||December 2007|
|Actual Study Completion Date :||December 2008|
No Intervention: Complete responders
watch and wait policy
Experimental: arm 2: complete responders patients
ABMT : TBI, 10 grays d-3-1 & cyclophosphamide 60 mg/sqm d-5-4
Procedure: Autologous stem cell transplantation
TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
Other Name: ABMT
Experimental: Non CR patients arm 3
Rescue chemotherapy and ABMT (see arm 2)
Procedure: DHAP rescue and Autologous stem cell transplantation
DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
Active Comparator: Non CR patients at random : arm 4
Rescue DHAP, F+C
Procedure: DHAP rescue and F+C
DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) & cyclophosphamide (300 mg/sqm)
- Progression free survival [ Time Frame: 3 year ]
- Overall survival, response after completion of scheduled treatment, tolerance and adverse events, quality of life, prognostic factors for response and survival. [ Time Frame: 36 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00931645
|DBIM Hopital Saint Louis|
|Paris, France, 75000|
|Principal Investigator:||Sutton Laurent, MD||Hospital Victor Dupouy Argenteuil, France|
|Study Chair:||Leporrier Michel, MD||CaenUH, France|